Intrathecal cell therapy with autologous stromal cells increases cerebral glucose metabolism and can offer a new approach to the treatment of Alzheimer's type dementia

Abstract Background aims After recent observations that intrathecal administration of autologous bone marrow mesenchymal stromal cells (MSCs) increases cerebral metabolism in patients with severe traumatic brain injury (TBI), we examined this type of cell therapy in Alzheimer's type dementia. M...

Full description

Saved in:
Bibliographic Details
Published in:Cytotherapy (Oxford, England) England), 2019-04, Vol.21 (4), p.428-432
Main Authors: VAQUERO, JESÚS, ZURITA, MERCEDES, MUCIENTES, JORGE, PASCUAL, MARIA L, FERNÁNDEZ-MATEOS, CECILIA, GARCIA, ESTEFANIA, FERNÁNDEZ-GUINEA, SARA
Format: Article
Language:English
Subjects:
Advanced Basic Science
Aged
Alzheimer Disease - diagnostic imaging
Alzheimer Disease - therapy
Alzheimer's disease
Brain - metabolism
cell therapy
dementia
Dementia - diagnostic imaging
Dementia - therapy
Female
Fluorodeoxyglucose F18 - metabolism
Glucose - metabolism
Humans
Injections, Spinal
Male
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells - cytology
Middle Aged
Other
Positron-Emission Tomography
Transplantation, Autologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background aims After recent observations that intrathecal administration of autologous bone marrow mesenchymal stromal cells (MSCs) increases cerebral metabolism in patients with severe traumatic brain injury (TBI), we examined this type of cell therapy in Alzheimer's type dementia. Methods Three patients with clinical diagnosis of Alzheimer's disease received every 3 months 100million autologous MSCs by intrathecal route, until a total dose of 300million. Results During cell therapy the patients showed arrest in neurological deterioration and two of them manifested clear improvement of previous symptoms. A global increase in cerebral glucose metabolism, measured using 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), was observed after every administration of cell therapy. Conclusions Our present findings suggest that intrathecal administrations of autologous MSCs can be a new strategy for the treatment of Alzheimer's dementia.
ISSN:1465-3249
1477-2566
DOI:10.1016/j.jcyt.2019.02.009